# Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

> **NCT00441350** · PHASE3 · COMPLETED · sponsor: **Menarini Group** · enrollment: 1004 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** OM 40
- **DRUG:** OM/HCTZ 40/12.5

## Key facts

- **NCT ID:** NCT00441350
- **Lead sponsor:** Menarini Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 1004 (ACTUAL)
- **Last updated:** 2021-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441350, "Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00441350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*